(Sharecast News) - Hutchmed China said in an update on Wednesday that it has completed patient enrollment in its phase three 'Sanovo' trial in China testing a combination of 'Orpathys', or savolitinib, and 'Tagrisso', or osimertinib, as a first-line therapy for certain non-small cell lung cancer patients.

• Read full story

• News Channel

(Sharecast News) - Hutchmed announced on Monday that China's National Medical Products Administration (NMPA) has approved the new drug application for the combination of 'Orpathys'. Or savolitinib, and 'Tagrisso', or osimertinib, to treat patients with locally advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer (NSCLC) with MET amplification following progression on EGFR TKI therapy.

• Read full story

• News Channel

(Sharecast News) - Hutchmed China and Innovent Biologics announced on Thursday that China's National Medical Products Administration had accepted a new drug application for a combination therapy using fruquintinib and sintilimab to treat advanced renal cell carcinoma in patients who have failed prior tyrosine kinase inhibitor treatment.

• Read full story

• News Channel